Interferon gamma-1b
- Generic Name
- Interferon gamma-1b
- Brand Names
- Actimmune
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- 98059-61-1
- Unique Ingredient Identifier
- 21K6M2I7AG
- Background
Human Interferon gamma-1b (140 residues), produced from E. coli. Production of Actimmune is achieved by fermentation of a genetically engineered Escherichia coli bacterium containing the DNA which encodes for the human protein. Purification of the product is achieved by conventional column chromatography.
The sequence displayed is a cDNA sequence which codes for human interferon gamma, as described by Gray et. al. and not specifically interferon gamma 1b.
- Indication
Interferon gamma-1b is used for the treatment of Chronic granulomatous disease and Osteopetrosis.
- Associated Conditions
- Chronic Granulomatous Disease (CGD), Severe, malignant Osteopetrosis
- Associated Therapies
- -
Topical Interferon Gamma for Macular Edema Secondary to Uveitis
- First Posted Date
- 2011-06-20
- Last Posted Date
- 2012-10-08
- Lead Sponsor
- National Eye Institute (NEI)
- Target Recruit Count
- 5
- Registration Number
- NCT01376362
- Locations
- 🇺🇸
National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States
Cell Responses to IFN-gamma
- Conditions
- First Posted Date
- 2011-03-16
- Last Posted Date
- 2013-03-05
- Lead Sponsor
- Rockefeller University
- Target Recruit Count
- 2
- Registration Number
- NCT01317017
- Locations
- 🇺🇸
Rockefeller University, New York, New York, United States
The Treatment of Uveitic Cystoid Macular Edema With Topical Interferon Gamma
- Conditions
- First Posted Date
- 2009-07-22
- Last Posted Date
- 2017-07-02
- Lead Sponsor
- National Eye Institute (NEI)
- Target Recruit Count
- 5
- Registration Number
- NCT00943982
- Locations
- 🇺🇸
National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States
An Open-Label Study of the Safety of Interferon Gamma-1b in Patients With IPF
- Conditions
- First Posted Date
- 2004-01-30
- Last Posted Date
- 2007-11-06
- Lead Sponsor
- InterMune
- Target Recruit Count
- 91
- Registration Number
- NCT00076635
- Locations
- 🇺🇸
Intermune Inc, Brisbane, California, United States
Safety of Interferon Gamma-1b With Rituximab in Non-Hodgkin's Lymphoma Patients
- Conditions
- First Posted Date
- 2003-04-03
- Last Posted Date
- 2007-11-01
- Lead Sponsor
- InterMune
- Target Recruit Count
- 24
- Registration Number
- NCT00057447
- Locations
- 🇺🇸
Intermune Inc, Brisbane, California, United States
Safety and Efficacy of Interferon Gamma-1b Plus Chemotherapy for Ovarian and Peritoneal Cancer
- Conditions
- First Posted Date
- 2002-10-11
- Last Posted Date
- 2007-11-01
- Lead Sponsor
- InterMune
- Target Recruit Count
- 847
- Registration Number
- NCT00047632
- Locations
- 🇺🇸
InterMune, Inc., Brisbane, California, United States
Safety and Efficacy of Inhaled Interferon Gamma-1b in Pulmonary MAC Infection
- Conditions
- First Posted Date
- 2002-08-12
- Last Posted Date
- 2007-11-01
- Lead Sponsor
- InterMune
- Target Recruit Count
- 100
- Registration Number
- NCT00043355
Study of Interferon Gamma-1b by Injection for the Treatment of Patients With Cystic Fibrosis
- Conditions
- First Posted Date
- 2002-08-12
- Last Posted Date
- 2007-11-01
- Lead Sponsor
- InterMune
- Target Recruit Count
- 51
- Registration Number
- NCT00043342
Interferon Gamma-1b by Inhalation for the Treatment of Patients With Cystic Fibrosis
- Conditions
- First Posted Date
- 2002-08-09
- Last Posted Date
- 2007-11-01
- Lead Sponsor
- InterMune
- Target Recruit Count
- 66
- Registration Number
- NCT00043316
Safety and Efficacy Study of Interferon Gamma-1b in Hepatitis C Patients With Liver Fibrosis or Cirrhosis
- Conditions
- First Posted Date
- 2002-08-09
- Last Posted Date
- 2007-11-01
- Lead Sponsor
- InterMune
- Target Recruit Count
- 502
- Registration Number
- NCT00043303
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.